Finance

Beta
Lists
IBT-B:STO
Infant Bacterial Therapeutics AB
SEK 56.00
-2.61%
(-1.50) 1D
Jun 4, 5:29:44 PM GMT+2  ·   SEK
All symbols
SymbolPriceChange% Change
Generating top insights for IBT-B...
Open
SEK 59.00
High
SEK 59.00
Low
SEK 54.20
Mkt. cap
729.02M
Avg. vol.
12.47K
Volume
2.12K
52-wk high
SEK 84.30
52-wk low
SEK 43.25
EPS
-SEK 5.30
Shares outstanding
13.02M
No. of employees
6
Open
SEK 59.00
High
SEK 59.00
Low
SEK 54.20
Mkt. cap
729.02M
Avg. vol.
12.47K
Volume
2.12K
52-wk high
SEK 84.30
52-wk low
SEK 43.25
EPS
-SEK 5.30
Shares outstanding
13.02M
No. of employees
6
News stories
From sources across the web
About Infant Bacterial Therapeutics AB
CEOStaffan Strömberg
Employees6
Founded2011
Headquarters-
SectorPharmaceutical industry
Websiteibtherapeutics.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
14.85M
6.01M
15.66M
18.69M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.28M
4.83M
4.88M
4.81M
Operating expense
20.13M
10.84M
20.54M
23.50M
Total operating expenses
20.13M
10.84M
20.54M
23.50M
Operating income
-20.13M
-10.84M
-20.54M
-23.50M
Other non operating income
-
1.00K
-1.00K
-563.44M
EBT including unusual items
-19.17M
-10.05M
-19.20M
-22.94M
EBT excluding unusual items
-19.17M
-10.05M
-19.20M
-22.94M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-19.17M
-10.05M
-19.20M
-22.94M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
954.00K
784.00K
1.34M
564.00M
Interest expense
-
-
-
-
Net interest expenses
954.00K
784.00K
1.34M
564.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer